Ticker CRVSListed on Nasdaq

Corvus Pharmaceuticals, Inc.

Pharmaceutical PreparationsCIK 0001626971South San Francisco, CaliforniaFilings at SEC EDGAR

At a glance

Most recent filing on November 13, 2026 — an open-market purchase by Arcara Jeffrey on Nov 13, 2026.

Since November 13, 2026: 4 open-market purchases and 0 open-market sales.

We hold 4 Form 4 lines, going back to November 13, 2026.

All 4 shown

  • Arcara Jeffrey Chief Business Officer
    $5,354Open-market buy
    TradedNov 13, 2026FiledNov 13, 2026
  • Arcara Jeffrey Chief Business Officer
    $5,216Open-market buy
    TradedNov 13, 2026FiledNov 13, 2026
  • Arcara Jeffrey Chief Business Officer
    $5,524Open-market buy
    TradedNov 12, 2026FiledNov 13, 2026
  • Arcara Jeffrey Chief Business Officer
    $34,381Open-market buy
    TradedNov 11, 2026FiledNov 13, 2026

CEO pay

What the company reported for its principal executive officer, usually the CEO, in the pay-versus-performance table of its proxy statement. The total counts shares and options at their value on the day they were granted. Actually paid counts them at the change in their value during the year, so it can be far higher or lower than the total, and negative. A dash means the company reported no amount.

Richard Miller, M.D., fiscal year ended Dec 31, 2025: total $7,031,566, actually paid $7,325,075. First reported Apr 24, 2026.

Earlier fiscal years are part of the subscription.